Preeclampsia prevention: choosing aspirin dose and timing
Preeclampsia is a pregnancy-specific hypertensive disorder that can affect the placenta, maternal organs, and fetal growth. It may appear after 20 weeks of gestation, during labor, or after delivery. Because the condition can progress quickly and may develop without obvious symptoms, prevention and early risk assessment are important parts of antenatal care.
Low-dose aspirin is one of the best-studied preventive options for pregnant patients at increased risk. Its potential benefit depends on more than simply taking a tablet: the reason for treatment, daily dose, gestational age when it begins, adherence, and individual safety factors all matter.
Research presented across perinatal and neonatal medicine has helped refine how clinicians think about placental disease and pregnancy complications. The scientific focus associated with the FAOPS 2020 congress archive reflects the wider importance of evidence-based care in maternal and newborn health, even though the planned Tokyo meeting was canceled during the COVID-19 pandemic.
Why aspirin is used in pregnancy
Preeclampsia involves abnormal placentation, impaired remodeling of the maternal spiral arteries, inflammation, endothelial dysfunction, and an imbalance between substances that promote and restrict blood-vessel activity. These processes can begin early, well before blood pressure rises or protein appears in the urine.
Aspirin irreversibly inhibits platelet cyclooxygenase and reduces thromboxane production. At low doses, it may support a more favorable balance between vasoconstrictive and vasodilatory pathways. The medication does not eliminate every cause of preeclampsia, and it is not a treatment for established severe disease. Its primary role is prevention in people whose clinical history or screening profile indicates elevated risk.
Large trials and guideline reviews generally show a modest reduction in preeclampsia risk among appropriately selected patients. The greatest benefit appears to occur when prophylaxis begins early enough to influence placental development and is taken consistently. Aspirin should therefore be viewed as one part of a broader plan that includes blood-pressure assessment, appropriate prenatal visits, and evaluation of fetal growth when indicated.
Who may benefit from prophylaxis
Guidelines commonly recommend low-dose aspirin for pregnant patients with one or more major risk factors. These may include a history of preeclampsia, especially when accompanied by an adverse outcome; a multifetal pregnancy; chronic hypertension; pregestational type 1 or type 2 diabetes; kidney disease; or autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome.
Several moderate-risk factors may also justify prophylaxis when they occur together. Examples include a first pregnancy, obesity, a family history of preeclampsia, maternal age of 35 years or older, a long interval between pregnancies, and certain social or demographic factors associated with reduced access to consistent prenatal care. The exact threshold varies among professional organizations and national guidelines.
Risk assessment should be individualized rather than based on a single checkbox. A previous uncomplicated pregnancy does not rule out preeclampsia in a later pregnancy, and the absence of risk factors does not guarantee that the disorder will not occur. Clinicians may also use first-trimester screening models that combine maternal characteristics, mean arterial pressure, uterine artery Doppler findings, and placental biomarkers.
Dose selection and the evidence behind it
The phrase “low-dose aspirin” covers a range of doses. In the United States, 81 mg daily is frequently prescribed, while studies and guidelines in other regions may use 75 mg, 100 mg, or 150 mg. The best dose depends partly on local tablet availability, clinical guidance, body size, risk level, and whether treatment is based on a screening algorithm.
Some research suggests that 150 mg daily may reduce preterm preeclampsia more effectively than lower doses in selected high-risk populations, particularly when started before 16 weeks. However, evidence is not completely uniform, and a higher dose is not automatically appropriate for every pregnant patient. Differences in trial design, adherence, patient characteristics, and aspirin formulation make direct comparisons difficult.
| Clinical consideration | Common approach | Important qualification |
|---|---|---|
| Standard preventive dose | 75–81 mg daily | Often used in routine guideline-based care |
| Higher-risk or screening-selected patients | 100–150 mg daily in some protocols | Requires clinician-directed selection |
| Starting point | Usually 12–16 weeks | Earlier initiation may be more beneficial |
| Stopping point | Often near delivery, according to local guidance | Timing should reflect bleeding risk and obstetric plans |
| Missed dose | Resume the regular schedule when remembered | Do not double doses without medical advice |
| Monitoring | Routine prenatal blood pressure and symptom assessment | Aspirin does not replace surveillance |
A dose comparison should never be separated from timing and adherence. Taking 150 mg inconsistently may provide less real-world benefit than taking a prescribed lower dose every day. Patients should avoid changing the dose independently, splitting or combining products without advice, or substituting pain-relief aspirin products that contain different strengths.
When treatment should begin
Many recommendations advise beginning aspirin between 12 and 28 weeks of gestation, with the strongest preventive rationale for starting by 16 weeks in patients who meet criteria. Early initiation may matter because placental vascular development and maternal adaptation are already underway during the first half of pregnancy.
Starting later may still be recommended when risk is recognized after 16 weeks. A late start should not be interpreted as useless, but expectations should be realistic: aspirin cannot reverse established placental disease, and its preventive effect may be smaller when begun after the period of early placentation.
The time of day is less settled than the gestational age at initiation. Some studies have explored bedtime dosing because platelet activity and blood pressure patterns vary across the day. Current practice often prioritizes a consistent daily routine over a universal morning or evening rule. Taking aspirin at the same time each day, with food if needed for stomach comfort, can make adherence easier.
Safety, contraindications, and clinical monitoring
Low-dose aspirin is generally well tolerated when prescribed appropriately, but it is not risk-free. Possible adverse effects include dyspepsia, easy bruising, nosebleeds, and gastrointestinal bleeding. Serious bleeding is uncommon in suitable patients, yet the risk can change with a bleeding disorder, thrombocytopenia, active peptic ulcer disease, liver disease, or use of anticoagulants and other antiplatelet medicines.
A history of aspirin or nonsteroidal anti-inflammatory drug allergy requires careful review. Aspirin-sensitive asthma, previous aspirin-related bronchospasm, and certain bleeding conditions may make prophylaxis unsuitable. The clinician should also review all prescription medicines, over-the-counter products, and supplements before treatment begins.
Aspirin prevention does not remove the need to recognize warning symptoms. Severe or persistent headache, visual changes, right upper abdominal pain, sudden swelling, shortness of breath, confusion, or markedly elevated blood pressure requires prompt medical assessment. Patients should follow local maternity guidance for urgent evaluation rather than waiting for the next routine appointment.
Whether aspirin is continued until delivery varies by guideline, clinician preference, planned induction or cesarean birth, and individual bleeding considerations. Some protocols continue it through delivery, while others advise stopping at a specified gestational age. This decision should be made by the obstetric team, particularly when neuraxial anesthesia, surgery, or a bleeding concern is anticipated.
Making prevention practical
The effectiveness of a preventive regimen depends heavily on implementation. Patients may stop aspirin because of nausea, misunderstanding, spotting, fear of medication exposure, or uncertainty about whether a missed dose matters. Clear counseling can address these concerns and distinguish expected minor effects from symptoms that require urgent care.
Clinicians should document the indication, selected dose, start date, allergies, concurrent medicines, and planned review. A simple medication routine, such as taking the tablet after an evening meal, may support regular use. However, the chosen schedule should fit the patient’s daily life and any instructions from the maternity team.
Useful principles include:
- Confirm the individual risk profile before starting prophylactic aspirin.
- Begin within the recommended gestational window, preferably by 12–16 weeks when clinically appropriate.
- Take the prescribed dose consistently and avoid doubling after a missed tablet.
- Review bleeding history, asthma, allergies, ulcers, kidney disease, and interacting medicines.
- Continue routine blood-pressure checks and seek urgent care for symptoms suggestive of preeclampsia.
Prevention also includes healthy prenatal care, although lifestyle measures cannot replace aspirin when a clinician has recommended it. Appropriate weight management before pregnancy, diabetes and hypertension control, smoking cessation, and attendance at antenatal appointments can support overall maternal health. Once pregnant, nutritional advice and physical activity should be tailored to the individual rather than presented as a guaranteed way to prevent preeclampsia.
Applying the evidence to different pregnancies
A patient with previous early-onset preeclampsia and a patient with a mildly elevated risk profile may both receive aspirin, but the clinical reasoning and follow-up intensity may differ. A screening-based program may recommend 150 mg, while a general guideline may favor 81 mg. These approaches can both be evidence-informed when matched to the population and protocol for which they were developed.
Research also continues to examine aspirin resistance, body weight, platelet biology, combination prevention strategies, and the value of biomarkers. These questions are important because preeclampsia is a collection of related syndromes rather than a single disease with one mechanism. Future studies may clarify which patients benefit from different doses and whether treatment should be adjusted during pregnancy.
For now, the most reliable approach is to combine established guidance with individualized assessment. Aspirin is neither a universal supplement nor a substitute for obstetric monitoring. It is a targeted preventive medicine whose value is greatest when started at the right stage, taken regularly, and integrated into a complete maternity-care plan.
Discuss personal eligibility, dose, starting date, and stopping instructions with a qualified pregnancy-care professional before taking aspirin. Use that conversation to create a clear plan for blood-pressure monitoring and urgent symptoms, so evidence about aspirin dosing and timing becomes a practical safeguard for maternal and fetal health.
